Patterson Cos., Inc. (PDCO), a distributor in the dental and animal health sectors, revealed on Wednesday that it has signed a definitive agreement to be acquired by the healthcare investment firm Patient Square Capital. The transaction will be conducted at $31.35 per share, amounting to an all-cash deal valued at approximately $4.1 billion, which includes the refinancing of Patterson's receivables facilities.
This per-share offer entails a roughly 49% premium over Patterson's 30-day volume-weighted average price as of December 4, 2024, the last trading day before the company disclosed its examination of strategic alternatives.
Patterson's decision to proceed with this transaction follows a comprehensive review of strategic alternatives by its Board of Directors, aided by its independent advisors. This move aims to maximize value and allow the company to continue successfully executing its strategic plans.
The company's Board of Directors, with the absence of President and CEO Don Zurbay due to his role as a Management Director, unanimously approved the acquisition. Zurbay has recused himself from any negotiations or approvals regarding this transaction.
Funding for the transaction will comprise a combination of equity financing committed by Patient Square Equity Partners, LP, and debt financing led by Citi, UBS Investment Bank, and Wells Fargo Bank N.A.
The transaction is anticipated to conclude in the fourth quarter of Patterson's fiscal year 2025, contingent on shareholder approval, regulatory approvals, and the fulfillment of other customary closing conditions.
The merger agreement incorporates a 40-day "go-shop" period, allowing Patterson's Board and its advisors to solicit alternative acquisition proposals from third parties actively.
Once the transaction is finalized, Patterson will become a privately held entity, and its common stock will cease trading on the NASDAQ Global Select Market. The company will continue to operate out of its headquarters in St. Paul, Minnesota.
The material has been provided by InstaForex Company - www.instaforex.com
This per-share offer entails a roughly 49% premium over Patterson's 30-day volume-weighted average price as of December 4, 2024, the last trading day before the company disclosed its examination of strategic alternatives.
Patterson's decision to proceed with this transaction follows a comprehensive review of strategic alternatives by its Board of Directors, aided by its independent advisors. This move aims to maximize value and allow the company to continue successfully executing its strategic plans.
The company's Board of Directors, with the absence of President and CEO Don Zurbay due to his role as a Management Director, unanimously approved the acquisition. Zurbay has recused himself from any negotiations or approvals regarding this transaction.
Funding for the transaction will comprise a combination of equity financing committed by Patient Square Equity Partners, LP, and debt financing led by Citi, UBS Investment Bank, and Wells Fargo Bank N.A.
The transaction is anticipated to conclude in the fourth quarter of Patterson's fiscal year 2025, contingent on shareholder approval, regulatory approvals, and the fulfillment of other customary closing conditions.
The merger agreement incorporates a 40-day "go-shop" period, allowing Patterson's Board and its advisors to solicit alternative acquisition proposals from third parties actively.
Once the transaction is finalized, Patterson will become a privately held entity, and its common stock will cease trading on the NASDAQ Global Select Market. The company will continue to operate out of its headquarters in St. Paul, Minnesota.
The material has been provided by InstaForex Company - www.instaforex.com